Chris Plummer
A5042298510- Cardiac pacing and defibrillation studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac Arrhythmias and Treatments
- Cancer Treatment and Pharmacology
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Imaging and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Cardiac electrophysiology and arrhythmias
- HER2/EGFR in Cancer Research
- Cancer-related cognitive impairment studies
- Peptidase Inhibition and Analysis
- Metabolism, Diabetes, and Cancer
- Amino Acid Enzymes and Metabolism
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Neurological disorders and treatments
- Innovations in Medical Education
- Health and Medical Research Impacts
- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Acute Myeloid Leukemia Research
- Sepsis Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Health Systems, Economic Evaluations, Quality of Life
- Cardiomyopathy and Myosin Studies
Freeman Hospital
2016-2025
Newcastle upon Tyne Hospitals NHS Foundation Trust
2010-2025
Newcastle University
2019-2025
NIHR Newcastle Biomedical Research Centre
2024-2025
Cumbria Northumberland Tyne and Wear NHS Foundation Trust
2024-2025
South Tees Hospitals NHS Foundation Trust
2025
James Cook University Hospital
2025
The University of Texas MD Anderson Cancer Center
2025
Byotrol (United Kingdom)
2021-2024
Newcastle upon Tyne Hospital
2005-2023
BackgroundAdjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant non-inferior the 12-month regarding disease-free survival.MethodsThis study an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in UK. randomly assigned cancer,...
Inhibition of monocarboxylate transporter (MCT) 1-mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part a first-in-human trial AZD3965, first-in-class MCT1 inhibitor, in advanced cancer.
More women are living with and surviving breast cancer, because of improvements in cancer care. Trastuzumab (Herceptin®▾) has significantly improved outcomes for HER2-positive tumours. Concerns about the cardiac effects trastuzumab (which fundamentally differ from permanent myocyte loss associated anthracyclines) led to development guidelines adjuvant trials, which used monitor patient safety clinical practice. Clinical experience shown that trial protocols not truly applicable population as...
BACKGROUND Cardiotoxicity is a concern for cancer survivors undergoing anthracycline chemotherapy.Enalapril has been explored its potential to mitigate cardiotoxicity in patients.The dose-dependent effects of anthracyclines can be detected early through the biomarker cardiac troponin. OBJECTIVESThe PROACT (Preventing Cardiac Damage Patients Treated Breast Cancer and Lymphoma) clinical trial assessed effectiveness enalapril preventing cardiotoxicity, manifesting as myocardial injury function...
Abstract Mobile health (mHealth) solutions have the potential to improve self-management and clinical care. For successful integration into routine practice, healthcare professionals (HCPs) need accepted criteria helping mHealth solutions’ selection, while patients require transparency trust their use. Information about evidence, safety security may be hard obtain consensus is lacking on level of required evidence. The new Medical Device Regulation more stringent than its predecessor, yet...
To evaluate the cost-effectiveness of implantable cardioverter defibrillators (ICDs), cardiac resynchronisation therapy pacemakers (CRT-Ps) and combination (CRT-D) in patients with heart failure reduced ejection fraction based on a range clinical characteristics.Individual patient data from 13 randomised trials were used to inform decision analytical model. A series regression equations predict baseline all-cause mortality, hospitalisation rates health-related quality life device-related...
Background Multiple long-term conditions (MLTCs; commonly referred to as multimorbidity) are highly prevalent among people admitted hospital and therefore of critical importance hospital-based healthcare systems. To date, most research on MLTCs has been conducted in primary care or the general population with comparatively little work undertaken setting. Purpose describe rationale content ADMISSION: a four-year UK Research Innovation National Institute Health Care funded interdisciplinary...